Results 11 to 20 of about 252 (105)

The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients. [PDF]

Rehabil Res Pract, 2012
Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and
Navarro JC, Molina MC, Baroque Ii AC, Lokin JK.   +3 more
europepmc   +7 more sources

Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial [PDF]

Stroke Research and Treatment, 2011
Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods.
A. A. Harandi, R. Abolfazli, A. Hatemian, K. Ghragozlee, M. Ghaffar-Pour, M. Karimi, S. Shahbegi, H. Pakdaman, M. Tabasi, A. L. Tabatabae, A. Nourian   +10 more
doaj   +4 more sources

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild‐to‐moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double‐blind, placebo‐controlled trial [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Background Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and ...
Christopher L.H. Chen, Purabi Reang Sharma, Boon Yeow Tan, Casuarine Low, Narayanaswamy Venketasubramanian   +4 more
doaj   +3 more sources

Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. [PDF]

Cerebrovasc Dis, 2018
Background and Purpose: MLC601 has been shown in preclinical studies to enhance neurorestorative mechanisms after stroke. The aim of this post hoc analysis was to assess whether combining MLC601 and rehabilitation has an effect on improving functional ...
Suwanwela NC, Chen CLH, Lee CF, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, Baroque Ii AC, Navarro JC, Chang HM, Advincula JM, Muengtaweepongsa S, Chan BPL, Chua CL, Wijekoon N, de Silva HA, Hiyadan JHB, Wong KSL, Poungvarin N, Eow GB, Venketasubramanian N, CHIMES-E Study Investigators.   +22 more
europepmc   +5 more sources

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial [PDF]

Dementia and Geriatric Cognitive Disorders Extra, 2015
Background: MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer's disease (AD) patients.
Hossein Pakdaman, Ali Amini Harandi, Hamidreza Hatamian, Mojgan Tabatabae, Hosein Delavar Kasmaei, Amirhossein Ghassemi, Koroush Gharagozli, Farzad Ashrafi, Pardis Emami Naeini, Mehrnaz Tavakolian, Darush Shahin   +10 more
doaj   +5 more sources

Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study [PDF]

Dementia and Geriatric Cognitive Disorders Extra, 2018
Background and Aim: Alzheimer disease (AD) is the most common cause of dementia. Currently, there is no disease-modifying therapy for AD. We aimed to evaluate the long-term efficacy and safety of MLC601 in the treatment of AD. Methods: In this open-label
Hossein Pakdaman, Koroush Gharagozli, Mehdi Abbasi, Ali Sobhanian, Ali Bakhshandehpour, Farzad Ashrafi, Mitra Khalilzad, Ali Amini Harandi   +7 more
doaj   +5 more sources

The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD). [PDF]

J Evid Based Med, 2015
© 2015 Chinese Cochrane Center, West China Hospital of Sichuan University and Wiley Publishing Asia Pty Ltd. Objective: The CHIMES Study compared MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours.
Venketasubramanian N, Lee CF, Wong KS, Chen CL.   +3 more
europepmc   +9 more sources

The Relationship between Ischemic Stroke Patients with and without Retroflex Tongue: A Retrospective Study [PDF]

Evidence-Based Complementary and Alternative Medicine, Volume 2017, Issue 1, 2017., 2017
Background. Patients suffering from stroke exhibit different levels of capability in retroflex tongues, in our clinical observation. This study aims to derive the association of tongue retroflexibility with the degree of severity for stroke patients ...
John Y. Chiang, Lun-Chien Lo, Mu-Chien Sun, Po-Chi Hsu, Yu-Liang Chen, Yung-Sheng Huang   +5 more
core   +3 more sources

Efficacy and safety of CDP-choline, cerebrolysin, MLC601, and edaravone in recovery of patients with acute ischemic strokes: a meta-analysis

Exploration of Neuroprotective Therapy, 2023
Aim: Stroke is the second most common cause of mortality and disability worldwide with ischemic strokes being the predominant type. The advent of neuroprotectants brought hope of improved outcomes and quality of life, but current guidelines, despite ...
Shafiq Dexter B. Abou Zaki, Johnny K. Lokin   +1 more
doaj   +2 more sources

A Systematic Search and Review of Registered Pharmacological Therapies Investigated to Improve Outcomes after a Stroke. [PDF]

Cerebrovasc Dis Extra
Introduction: Stroke burden is largely due to long-term impairments requiring prolonged care and loss of productivity. We aim to identify and assess studies of different registered pharmacological therapies as treatments for improving post-stroke ...
Lee TH, Uchiyama S, Kusuma Y, Chiu HC, Navarro JC, Tan KS, Pandian JD, Guo L, Wong Y, Venketasubramanian N, Asian Stroke Advisory Panel.   +10 more
europepmc   +3 more sources